Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss biopharmaceutical company Basilea Pharmaceutica has applied for EU marketing authorization for alitretinoin in severe refractory chronic hand eczema.
Subscribe to our email newsletter
The marketing authorization applications seek approval for oral alitretinoin in the treatment of severe refractory chronic hand eczema and are based on a clinical program comprising almost 2,000 patients.
Dr Anthony Man, CEO of Basilea, said: “We intend to build a fully integrated hospital and specialty care business focused on serving high medical needs. The submission of our second European product marketing authorization application this year is another significant step towards our goal.”